Related Experiment Video
Updated: Jan 21, 2026
08:27
Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits
Published on: September 27, 2019
7.2K
Examining Predisposing Factors and Program Performance Indicators Associated With Program Completion: A Comparison of
Lisa M Shannon1, Afton Jackson Jones1, Jennifer Newell1
1Morehead State University, Morehead, KY, USA.
Summary
Drug court completion differs for opioid users. For non-opioid users, personal factors and program performance matter. For opioid users, only program performance impacts success.
Area of Science:
- Criminal Justice
- Psychology
- Public Health
Background:
- Opioid use and criminal justice involvement have risen significantly.
- Drug courts offer community-based rehabilitation for substance abuse issues within the justice system.
- Unique treatment needs of opioid users necessitate tailored drug court approaches.
Purpose of the Study:
- To investigate predisposing factors and program performance indicators linked to drug court completion.
- To compare these factors between opioid-preferring and non-opioid-preferring participants.
- To identify specific elements influencing successful rehabilitation outcomes in drug courts.
Main Methods:
- Analysis of secondary data from participant assessments and drug court Management Information Systems.
- Inclusion of conviction information from a statewide database.
- Comparison of opioid-preferring (n=267) and non-opioid-preferring (n=267) participants (N=534).
Main Results:
- For non-opioid-preferring participants, drug court completion was influenced by social/demographic factors (education, site) and substance use (benzodiazepine use), alongside program performance (days in court, drug tests, sanctions).
- For opioid-preferring participants, only program performance indicators (days in court, drug tests, sanctions) significantly influenced completion.
- This highlights a divergence in factors affecting successful drug court outcomes based on substance preference.
Conclusions:
- Predisposing characteristics and program performance are key for non-opioid-preferring individuals in drug court.
- For opioid-preferring individuals, program performance is the sole significant predictor of drug court completion.
- Findings support individualized drug court planning for enhanced participant success and rehabilitation outcomes.
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
952
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
952
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
630
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
630
01:22Opioid Receptors: Overview
4.1K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.1K
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
886
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
886
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
154
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
154
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
456
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
456